Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edgar Dippel

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
The Lancet. Haematology|February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialRudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Guidelines - Cutaneous lymphomas (ICD10 C82 - C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 21, 2022
S2k-Leitlinie - Kutane Lymphome (ICD10 C82-C86): Update 2021Edgar Dippel, Chalid Assaf, Jürgen C Becker, et al.
Cancers|February 15, 2022
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or ToxicityElias A T Koch, Anne Petzold, Anja Wessely, et al.
The Lancet. Haematology|February 6, 2026
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trialRudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanomaGeorg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Pageof 10